Athira Pharma Inc (NAS:ATHA)
$ 0.5102 0.0198 (4.04%) Market Cap: 19.60 Mil Enterprise Value: -71.51 Mil PE Ratio: 0 PB Ratio: 0.23 GF Score: 42/100

Athira Pharma Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 26, 2023 / 02:30PM GMT
Release Date Price: $1.96 (-1.01%)
Charles Duncan
Cantor Fitzgerald & Co. - Analyst

I think we should get started on the next presenting panel. So I'm Charles, I'm a senior biotech analyst with Cantor, and it's a pleasure to introduce the next presenting panel that is comprised of two folks who I've known for quite some time. They're doing some pretty innovative work in neurodegenerative diseases. Both of them with a broad platform that is focused on inflammation.

So why conduct this panel? Well, because I think for neurodegenerative diseases, neurology, even psychiatry, inflammation is important and is perhaps one of the components of etiology that really drives disease progression. So it's a pleasure to introduce Mr. Mark Litton, the CEO -- President and CEO of Athira Pharma. Mark, nice to see you. Thanks for joining.

Mark Litton
Athira Pharma Inc - President&CEO

Hello.

Charles Duncan
Cantor Fitzgerald & Co. - Analyst

And Mr. Cuong Do, the President and CEO of BioVie. Cuong, great to have you. Thanks for joining.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot